Blood Pressure on TRT: What the Evidence Actually Shows

Does TRT Actually Raise Blood Pressure?

The short answer: not reliably, and probably not through a direct pressor mechanism. Blood pressure changes on TRT are mostly secondary, driven by rising red-cell mass, sodium retention from aromatization to estradiol, and pre-existing cardiovascular disease rather than testosterone acting directly on vessel walls. A 2016 meta-analysis in Hypertension Research (18 RCTs, N=1,862) found a weighted mean systolic reduction of 2.0 mmHg and no statistically significant diastolic change with testosterone therapy versus placebo [1]. That is a modest signal, and it cuts in the opposite direction from the feared hypertensive effect.

Where the risk is real is in men who develop erythrocytosis (hematocrit >54%), because whole-blood viscosity rises sharply at that threshold and can increase both peripheral resistance and clot risk [2]. The FDA label for testosterone products explicitly warns about this and sets dose-reduction or discontinuation criteria accordingly [3].

Two earlier observational studies (one a 2010 Veterans Affairs cohort of 8,709 men) suggested increased cardiovascular events with TRT, generating years of clinical hesitation [4]. Those studies had major confounders: patients were older, had higher baseline comorbidity burdens, and many received supraphysiologic doses. The TRAVERSE trial addressed those gaps directly.

What TRAVERSE Actually Found

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) randomized 5,246 men aged 45, 80 with confirmed hypogonadism (two morning total testosterone readings <300 ng/dL) and either established cardiovascular disease or high cardiovascular risk to testosterone undecanoate 750 mg IM or matching placebo [5]. Median follow-up was 33 months.

The primary endpoint, major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or cardiovascular death), occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78, 1.17), confirming noninferiority [5]. Blood pressure did not differ meaningfully between groups at any follow-up visit.

Two safety signals deserve attention. Pulmonary embolism occurred in 0.9% of the testosterone group versus 0.5% in the placebo group (HR 1.92) [5]. Atrial fibrillation and acute kidney injury also occurred at higher rates in the testosterone arm. These findings, published in the New England Journal of Medicine in 2023, shaped the FDA's updated prescribing guidance the same year [6].

The American Urological Association interpreted TRAVERSE as evidence that TRT is cardiovascularly safe for most men with confirmed hypogonadism but cautioned that the pulmonary embolism and atrial fibrillation signals require individualized risk assessment before initiating therapy [7].

Understanding Total Testosterone: What Your Lab Value Means

Total testosterone measures every testosterone molecule in circulation: the fraction bound to sex hormone-binding globulin (SHBG), the fraction loosely bound to albumin, and the small free fraction. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism defines the lower limit of the normal range as 300 ng/dL, based on the Framingham Heart Study reference population using a liquid chromatography-mass spectrometry (LC-MS/MS) platform [8].

Reference ranges vary by assay and laboratory. Quest Diagnostics and LabCorp both report 264 to 916 ng/dL and 348, 1 to 197 ng/dL respectively for adult men, differences that reflect platform calibration, not biology. Clinicians should interpret a patient's result against the specific lab's reference interval and always use LC-MS/MS rather than immunoassay for accuracy at low concentrations [8].

Two morning draws on separate days are required before diagnosing hypogonadism, because testosterone follows a diurnal rhythm with peak levels between 7, 10 a.m. and a trough that can be 30 to 35% lower by late afternoon [9]. A single low result on an afternoon draw is not diagnostic.

TRT targets vary slightly by route and prescriber preference, but most protocols aim for a mid-cycle total testosterone of 500 to 900 ng/dL. Levels above 1 to 000 ng/dL on standard-dose therapy should prompt dose reduction, because supraphysiologic exposure accelerates erythrocytosis and may raise blood pressure via the hematocrit pathway [3].

Free Testosterone Calculation: Why Total T Is Sometimes Not Enough

Only 2 to 3% of testosterone circulates as free, unbound hormone in men [10]. The rest attaches to SHBG (roughly 44 to 65%) or albumin (roughly 33 to 54%). Only free testosterone and albumin-bound testosterone can enter target cells; SHBG-bound hormone is biologically inactive at the receptor level.

A man with a total testosterone of 350 ng/dL and an SHBG of 15 nmol/L may have adequate free testosterone and no symptoms. A different man with the same total T but an SHBG of 60 nmol/L (common in obesity, hyperthyroidism, or aging) may have profoundly low free testosterone and clear hypogonadal symptoms [10]. Treating total T alone misses that distinction.

The Vermeulen equation remains the most validated method for calculating free testosterone from total testosterone, SHBG, and albumin (assumed 4.3 g/dL) [11]. Many academic labs now offer this as a calculated free testosterone report alongside the total. Equilibrium dialysis is the gold-standard direct measurement but is expensive and rarely available outside research settings.

Normal calculated free testosterone in adult men using the Vermeulen formula runs approximately 5 to 21 ng/dL (50, 210 pg/mL), though some guidelines place the lower limit of normal closer to 65 pg/mL on sensitive assays. The Endocrine Society recommends measuring free or bioavailable testosterone in men whose total T falls in the low-normal range (300 to 400 ng/dL) but who have clear symptoms [8].

A practical three-step decision framework used by the HealthRX medical team:

1. If total testosterone is <300 ng/dL on two morning draws using LC-MS/MS, diagnose hypogonadism without further calculation.
2. If total testosterone is 300 to 400 ng/dL with symptoms, calculate free testosterone via the Vermeulen equation. Treat if calculated free T falls below 65 pg/mL.
3. If total testosterone is >400 ng/dL, pursue other causes of the patient's symptoms before starting TRT.

Estradiol on TRT: The Sensitive Assay Requirement

Testosterone aromatizes to estradiol (E2) in peripheral fat tissue. On exogenous testosterone, estradiol levels rise, and high E2 contributes to fluid retention, which can nudge blood pressure upward in susceptible men [12]. Gynecomastia, mood changes, and reduced libido at high doses are also E2-mediated.

Measuring estradiol in men requires the sensitive estradiol assay (also called the third-generation assay or LC-MS/MS E2), not the standard immunoassay designed for women. Standard immunoassays lose precision below 50 pg/mL and frequently report falsely elevated E2 in men, leading to unnecessary aromatase inhibitor (AI) use [13]. The Endocrine Society specifically recommends against routine use of standard immunoassay E2 in males [8].

Target E2 on TRT is generally 20, 40 pg/mL by sensitive assay. Values above 40 pg/mL in the presence of symptoms warrant dose reduction, switch to a less aromatizing route (e.g., from IM depot to daily transdermal), or addition of a low-dose AI such as anastrozole 0.25 to 0.5 mg twice weekly. Values below 20 pg/mL, sometimes caused by over-aggressive AI use, carry their own risks: bone mineral density loss and potentially adverse lipid changes [14].

Routine E2 monitoring frequency on stable TRT: at baseline, at 3 months after any dose change, and then every 6 to 12 months if stable [8].

CBC on TRT: Hematocrit, Hemoglobin, and Why They Matter for Blood Pressure

Testosterone directly stimulates erythropoietin (EPO) production in the kidneys and suppresses hepcidin, both of which drive red-cell mass upward [15]. This effect is therapeutically useful in men with anemia of chronic disease but becomes a liability when hematocrit climbs too high.

At hematocrit levels above 50%, whole-blood viscosity rises in a nonlinear fashion. By 54%, peripheral vascular resistance increases enough to contribute meaningfully to blood pressure elevation and to substantially increase thrombotic risk [2]. This, not a direct vasopressor effect of testosterone on vascular smooth muscle, is the dominant mechanism behind TRT-associated blood pressure concern in clinical practice.

The FDA label for all testosterone products (including testosterone cypionate, testosterone enanthate, and testosterone undecanoate) instructs clinicians to check hematocrit before therapy and at 3 to 6 month intervals during the first year, then annually [3]. Dose reduction is recommended when hematocrit exceeds 54%. Therapeutic phlebotomy is an option for men who remain erythrocytotic at a reduced dose.

A complete blood count (CBC) on TRT should include:

• Hemoglobin and hematocrit (primary erythrocytosis screen)
• MCV (rising MCV can precede hematocrit elevation)
• Platelet count (thrombocytopenia is rare but reported)
• WBC differential (baseline reference for immune competence)

Hematocrit typically rises within the first 3 months of TRT and plateaus by 6 to 12 months in most men [15]. Men with sleep apnea, smokers, and men at altitude reach erythrocytotic thresholds faster than the general TRT population and require more frequent CBC surveillance.

A 2013 study in the Journal of Clinical Endocrinology and Metabolism (N=303) found that polycythemia (hematocrit >50%) developed in 5.7% of men receiving testosterone gel and 12.2% of men receiving IM testosterone at 36 months, illustrating how route of administration affects this risk [16].

Blood Pressure Monitoring Protocol on TRT

The 2017 AHA/ACC guideline defines stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg [17]. That threshold applies to TRT patients. Clinicians should not wait for a reading of 140/90 before acting.

Recommended monitoring schedule:

• Baseline blood pressure before starting TRT.
• Recheck at the 6-week visit (approximately one full injection cycle for weekly IM protocols).
• Recheck at 3 months and 6 months during the first year.
• Annual measurements thereafter if stable.

Home blood pressure monitoring with a validated upper-arm device adds clinically useful data between clinic visits. A 2019 systematic review in the Journal of Hypertension confirmed that home readings predict cardiovascular outcomes better than single-office readings [18].

If blood pressure rises above 130/80 mmHg after starting TRT, the first steps are:

1. Check hematocrit. If >54%, reduce dose before adding an antihypertensive.
2. Check estradiol (sensitive assay). If >40 pg/mL with fluid retention symptoms, address aromatization.
3. Review sodium intake, alcohol use, and sleep apnea status, all of which interact with TRT to worsen blood pressure.
4. If blood pressure remains elevated after 8 weeks of those adjustments, standard antihypertensive therapy applies. ACE inhibitors or ARBs are generally preferred in this population because they also protect renal function in men with metabolic syndrome, which frequently coexists with hypogonadism [19].

Who Faces Higher Blood Pressure Risk on TRT

Not every man on TRT carries equal risk. The following groups need closer surveillance intervals and lower thresholds for intervention.

Men with pre-existing hypertension make up a large share of TRT candidates because hypogonadism and metabolic syndrome cluster together. TRAVERSE enrolled men who already had or were at high risk for cardiovascular disease, which is why its reassuring MACE data are particularly relevant to this population [5].

Men with obstructive sleep apnea (OSA) face compound risk. TRT worsens OSA in some patients by increasing upper-airway soft tissue volume, and undertreated OSA is an independent driver of nocturnal hypertension [20]. Men with OSA should have CPAP compliance confirmed before and during TRT.

Men using supraphysiologic doses, including those obtaining testosterone outside a supervised medical program, have hematocrit and blood-pressure risk profiles that differ sharply from men maintained in a normal physiologic range. The TRAVERSE data do not generalize to illicit or bodybuilding-dose testosterone use.

Older men (age >65) experience greater erythrocytotic response to testosterone at any given dose [15], which means the hematocrit risk accrues faster. The Endocrine Society's 2018 guideline notes that evidence of benefit in men older than 65 is less strong than in younger hypogonadal men, and recommends extra caution regarding cardiovascular and thrombotic risk [8].

Aromatase Inhibitors, Blood Pressure, and the Estrogen Balance Problem

Some TRT protocols include anastrozole or exemestane to limit estradiol rise. Using an AI aggressively, targeting E2 below 15, 20 pg/mL, is not supported by evidence and may be counterproductive for blood pressure. Estradiol has vasodilatory effects in men via nitric oxide pathways, and suppressing it too deeply removes that protection [21].

A 2021 study in the Journal of the Endocrine Society (N=198) found that men on TRT who used concurrent AIs had significantly lower bone mineral density Z-scores at 24 months compared to men on TRT alone, without demonstrable cardiovascular benefit from the AI [14]. Routine AI use for all TRT patients is not recommended by either the Endocrine Society or the American Urological Association.

AI use may be appropriate for men with symptomatic hyperestrogenism (gynecomastia, significant fluid retention, mood instability) confirmed by a sensitive E2 assay above 40 pg/mL. The dose should be the lowest effective amount, and E2 should be rechecked 6 weeks after initiation.

Drug Interactions That Can Affect Blood Pressure on TRT

Several commonly prescribed medications alter the blood-pressure picture for men on TRT.

Sildenafil and tadalafil, frequently used alongside TRT for erectile dysfunction, are vasodilators. Combining them with testosterone in a man with borderline-low blood pressure can produce symptomatic hypotension. Blood pressure should be checked at baseline and after adding a PDE5 inhibitor [22].

NSAIDs (ibuprofen, naproxen) cause sodium and water retention independently of testosterone and can raise blood pressure 3 to 5 mmHg in chronic users [23]. Men on TRT who also use daily NSAIDs need blood pressure monitored more frequently.

Corticosteroids, whether prescribed for inflammatory disease or misused for recovery, can drive fluid retention and blood pressure elevation that compounds the erythrocytotic effect of testosterone.

Full Lab Panel Recommended at Each Monitoring Interval

The table below describes the standard HealthRX monitoring protocol for men on TRT, based on Endocrine Society 2018 and AUA 2018 guideline recommendations [7, 8].

Baseline (before first dose): Total testosterone (LC-MS/MS, two morning draws), free testosterone (calculated or dialysis), SHBG, LH, FSH, estradiol (sensitive assay), CBC, comprehensive metabolic panel, PSA, lipid panel, blood pressure.

3 months: Total testosterone (trough for weekly IM, 2-hour post-application for transdermal), hematocrit, hemoglobin, estradiol (sensitive assay), blood pressure. PSA if >40 years old.

6 months: Full repeat of baseline panel. Adjust dose based on total and free testosterone, hematocrit, and E2.

12 months and annually: Full panel as at 6 months. DXA bone density scan if baseline was low or patient is >50 years old [8].

Specific Testosterone Formulations and Their Blood Pressure Profiles

Route of administration affects the blood-pressure-relevant variables, primarily hematocrit and estradiol, in distinct ways.

Testosterone cypionate or enanthate (IM, weekly): Produces higher peak-to-trough fluctuations. Peaks can transiently exceed 1 to 000 ng/dL, increasing aromatization and erythrocytotic drive. Hematocrit elevation is more common than with transdermal routes [16].

Testosterone undecanoate (IM, every 10 weeks): Provides stable serum levels with lower peak-to-trough ratio. This is the formulation used in TRAVERSE and showed no significant blood pressure difference versus placebo [5].

Testosterone gel or cream (transdermal, daily): Produces the most stable daily levels with the lowest hematocrit elevation rate (5.7% at 36 months versus 12.2% for IM in the 2013 JCEM study) [16]. A reasonable first choice for men with borderline-elevated hematocrit or pre-existing hypertension.

Testosterone pellets (subcutaneous, every 3 to 6 months): Provide sustained release. Dose titration after implantation is not possible until the pellets resorb, which limits the ability to respond quickly to adverse lab findings.

The AUA 2018 guideline on testosterone deficiency states: "Clinicians should counsel patients that testosterone therapy will be required on an ongoing basis and that there may be adverse effects with its use" and specifically lists polycythemia and cardiovascular events as harms requiring monitoring [7].